explore -WSS

explore

author：comprehensive 2025-09-27 15:20:51 - browse：19278

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： As Taiwan prepares for anti

WSS

Long Covid needs a new name — and a new frame

Review: 'Barbie' will hit you like a shot in the heart

CDC backtracks, saying fully vaccinated people can go maskless indoors

FDA official pushes for dedicated emerging pathogens team

New rules on organ donation and transplantation 'will bring chaos'

What to know about Saharan dust affecting the US and how it can affect health

entertainment

explore

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

In new study, freeze

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Regeneron agrees to White House price limits on anti

Anesthesiologist group: stop taking Ozempic before surgery

Providers still hesitate to prescribe buprenorphine, study finds

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Long Covid needs a new name — and a new frame

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

AbbVie dramatically boosts its spending on lobbying

leisure time

PEPFAR is under serious threat — and so is global health

Review: 'Barbie' will hit you like a shot in the heart

Providers still hesitate to prescribe buprenorphine, study finds

Will.i.am, Britney Spears release new single, 'Mind Your Business'

FDA proposes changes to key medical devices approval pathway

Generate Biomedicines machine learning biotech raises $273M

hotspot

knowledge

focus

explore